HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Menogaril

A semisynthetic anthracycline with the amino sugar on the D ring. It displays broad-spectrum antineoplastic activity against a variety of tumors.

Also Known As:

7-O-Methylnogarol; 7-OMEN; 7-con-O-Methylnogarol; Menogaril, (11 beta)-Isomer; Menogaril, (13 beta)-Isomer; Menogaril, (5 alpha)-Isomer; Menogaril, (5 alpha,11 beta)-Isomer; Menogarol; NSC-269148; TUT-7; Tomosar; NSC 269148; NSC269148; TUT 7; TUT7; 2,6-Epoxy-2H-naphthaceno(1,2-b)oxocin-9,16-dione, 4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-, (2R-(2alpha,3beta,4alpha,5beta,6alpha,11alpha,13alpha))-

Networked: 71 relevant articles (7 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Citrin, D L: 1 article (04/2001)
2.	Carbone, P: 1 article (04/2001)
3.	Manola, J: 1 article (04/2001)
4.	Trump, D L: 1 article (04/2001)
5.	Hudes, G R: 1 article (04/2001)
6.	Khandekar, J D: 1 article (04/2001)
7.	Obasaju, C: 1 article (04/2001)
8.	Kucuk, O: 1 article (08/2000)
9.	Benson, A B: 1 article (08/2000)
10.	Blough, R: 1 article (08/2000)

Related Diseases

1.	Neoplasms (Cancer) 11/01/1992 - "These results suggest that menogaril may be effective against stomach and breast cancers when orally administered." 07/01/1997 - "A phase I study with TUT-7, a new anthracycline antitumor antibiotic, was conducted in 35 malignant tumor patients at 11 institutions nationwide. " 02/01/1993 - "Thirty-five patients with advanced refractory cancer were enrolled on this phase I study of menogaril administered orally every 4 weeks at dosages ranging from 85 mg/m2 to 625 mg/m2. " 02/01/1990 - "Forty-seven patients with solid tumors were treated on a phase I study of menogaril administered by mouth once per week. " 12/01/1989 - "Thirty-nine adults with solid tumors were treated on a Phase I study of menogaril administered i.v. once each week. "
2.	Breast Neoplasms (Breast Cancer) 03/01/1992 - "The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of weekly oral menogaril as first-line therapy in 51 patients with incurable, metastatic or locally advanced breast cancer. " 08/01/1990 - "We conclude menogaril is active in breast cancer and recommend that because it can be delivered in high doses orally, future trials in this disease should focus on intense oral schedule." 09/07/1988 - "Phase II study of intravenous menogaril in patients with advanced breast cancer." 03/01/1992 - "In summary, menogaril is an anthracycline derivative that has modest activity when administered orally to minimally pretreated patients with breast cancer." 08/01/1990 - "Menogaril at this dose and schedule has modest activity as first line therapy for metastatic breast cancer but also has significant marrow and local toxicity."
3.	Lymphoma (Lymphomas) 01/01/1999 - "Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial." 09/01/1996 - "In this basic study, we examined the antitumor activity of menogaril against malignant lymphoma. " 09/01/1996 - "Menogaril rapidly penetrated lymphoma cells and remained there at least 3 hours after the drug was washed out. " 09/01/1996 - "Therefore, Menogaril might become a useful drug for the treatment of patients with malignant lymphoma by oral administration; 7 days of administration was effective in the in vivo experiments." 09/01/1996 - "Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice."
4.	Carcinoma (Carcinomatosis) 04/01/1989 - "Phase II study of intravenous menogaril in advanced ovarian carcinoma. " 06/01/1987 - "This study illustrates that at least two agents--menogarol and 4'-epirubicin--may have some antitumor activity against pancreatic carcinoma in this system." 11/01/1991 - "Phase II evaluation of menogaril in patients with advanced cervical carcinoma. " 08/15/1991 - "Menogaril, as administered in this protocol, had modest antineoplastic activity in previously treated ovarian carcinoma patients. " 08/15/1991 - "A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. "
5.	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/01/1991 - "The NCI Canada Clinical Trials Group conducted a phase II study of menogaril given intravenously every 4 weeks in low-grade non-Hodgkin's lymphoma. " 02/01/1991 - "A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. " 01/01/1999 - "The observed antitumor activity of single agent menogaril against both intermediate/high-grade and low-grade lymphomas was modest. " 01/01/1999 - "To assess the efficacy and toxicity of menogaril against non-Hodgkin's lymphoma (NHL) in a group of previously treated patients. " 08/01/1997 - "With these results, menogaril was considered to be effective for the treatment of non-Hodgkin's lymphoma and ATLL."

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Nogalamycin
3.	Fluorouracil (Carac)
4.	Cyclophosphamide (Cytoxan)
5.	Paclitaxel (Taxol)
6.	Cytotoxins
7.	Menogaril
8.	Anthracyclines
9.	Interferon-beta
10.	Platinum

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Oral Administration
3.	Drug Therapy (Chemotherapy)
4.	Intravenous Infusions
5.	Catheters